Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by dt_coreon Feb 09, 2011 1:49pm

201 Views

Post# 18103071

RE: RE: Great

It wasn't Dundee, it was Fraser Mack. They have been dead wrong in calling the stock and had a target price of
.60 for most of the run-up in the share price. Now the stock is around $1.50 so they threw in the towl and raised their target (as mentioned before, the sales desk at Fraser Mack is probably furious at the analysts poor performance).

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports